2:56 PM
 | 
Jan 25, 2019
 |  BioCentury  |  Finance

Venrock spreads HAE bets

Why Venrock picked Attune for its latest oral HAE investment

Venrock is broadening its portfolio of oral hereditary angioedema therapy investments by leading a $23 million series B round that will allow Attune Pharmaceuticals to move its lead plasma kallikrein (KLKB1) inhibitor into Phase II testing.

Venrock was an early investor in HAE company Dyax Corp., which was acquired by Shire plc and is now part of Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK). Dyax's HAE program became Takhzyro lanadelumab, an infusion which was approved in 2018 in the U.S. and E.U. as a prophylactic.

According to Attune's co-founder and...

Read the full 424 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >